volociximab volociximab volociximab (also known as m200) is a chimeric monoclonal antibody jointly developed by pdl biopharma and biogen idec for treatment of a variety of advanced solid tumors. it binds to and inhibits the functional activity of α5β1 integrin. volociximabmonoclonal antibodytypewhole antibodysourcechimeric (mouse/human)targetα5β1 integrinclinical dataatc codenoneidentifierscas number558480-40-3 nchemspidernoneunii496k5z02nwkeggd06319 ychemical and physical dataformulac6434h9942n1706o2040s52molar mass145501.33 g·mol−1 ny (what is this?) (verify) it is thought to reduce metastases. early results show potential in renal cell cancers.